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Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of
aggressive non-Hodgkin lymphomas with poor outcomes on current
therapy. We investigated whether response assessed with PET/CT
combined with baseline total metabolic tumor volume (TMTV) could
detect early relapse or refractory disease. Methods: From 7 European
centers, 140 patients with nodal PTCL who underwent baseline PET/CT
were selected. Forty-three had interim PET (iPET) performed after
2 cycles (iPET2), 95 had iPET performed after 3 or 4 cycles (iPET3/4),
and 96 had end-of-treatment PET (eotPET). Baseline TMTV was com-
puted with a 41% SUVmax threshold, and PET response was reported
using the Deauville 5-point scale. Results: With a median of 43 mo of
follow-up, the 2-y progression-free survival (PFS) and overall survival
(OS) were 51% and 67%, respectively. iPET2-positive patients (Deau-
ville score $ 4) had a significantly worse outcome than iPET2-negative
patients (P , 0.0001, hazard ratio of 6.8 for PFS; P , 0.0001, hazard
ratio of 6.6 for OS). The value of iPET3/4 was also confirmed for PFS
(P , 0.0001) and OS (P , 0.0001). The 2-y PFS and OS for iPET3/4-
positive (n5 28) and iPET3/4-negative (n5 67) patients were 16% and
32% versus 75% and 85%, respectively. The eotPET results also
reflected patient outcome. A model combining TMTV and iPET3/4
stratified the population into distinct risk groups (TMTV # 230 cm3
and iPET3/4-negative [2-y PFS/OS, 79%/85%]; TMTV . 230 cm3 and
iPET3/4-negative [59%/84%]; TMTV # 230 cm3 and iPET3/4-positive
[42%/50%]; TMTV. 230 cm3 and iPET3/4-positive [0%/18%]).Conclu-
sion: iPET response is predictive of outcome and allows early detection
of high-risk PTCL patients. Combining iPET with TMTV improves risk
stratification in individual patients.
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Peripheral T-cell lymphoma (PTCL) encompasses a heteroge-
neous and rare group of aggressive lymphomas derived from
postthymic T cells. PTCL represents only 10%–15% of all non-
Hodgkin lymphomas, pooling many different clinical–pathologic
subtypes. Nodal subtypes, or subtypes with characteristic nodal
involvement, are the most frequent subtypes encountered in white
patients and account for 80% of these aggressive lymphomas
(1,2). They include 4 distinct entities: PTCL not otherwise spec-
ified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL),
and anaplastic large cell lymphoma (ALCL), either anaplastic
lymphoma kinase (ALK)–positive or ALK-negative. PTCLs ex-
hibit a poor outcome (3), with an estimated overall survival (OS)
of 4.5 y and progression-free survival (PFS) of 47%–70% or 38%–
61%, depending on subtype (4). The treatment approach has tra-
ditionally been based on CHOP (cyclophosphamide, doxorubicin,
vincristine, and prednisone) or a CHOP-like regimen (2 mini-
CHOP, 18 CHOEP, 1 COEP, 1 COPADEM). However, the overall
response rate is only 70%. Early progression is observed in at least
30% of patients, who exhibit a very poor outcome and are not
candidates for autologous stem cell transplantation or any other
consolidation therapy (4). Therefore, there is an urgent need for
earlier identification of these high-risk chemoresistant patients to
provide them with alternative treatment strategies. Different prog-
nostic models have been proposed without affecting current treat-
ment recommendations. Recently, we reported that total metabolic
tumor volume (TMTV) as an estimate of the total tumor burden
was predictive of outcome in PTCL (5) and may assist the early
detection of high-risk patients. Detecting these patients using 18F-
FDG PET/CT for response assessment during the first few cycles
of chemotherapy (interim PET [iPET]) would be another prognos-
tic approach. iPET is predictive of outcome in diffuse large B-cell
lymphoma (6) and Hodgkin lymphoma (7), in which it has been
successfully used to guide the treatment strategy (8). In PTCL,
data concerning early response assessment with iPET are limited,
as are the data on PET at the end of treatment (eotPET) for re-
mission assessment. Studies have included relatively small num-
bers of patients with few comparisons between iPET and eotPET,
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with conflicting results (9–15). In this study, we evaluated the
predictive value of PET restaging—both iPET and eotPET—and
ascertained whether treatment response could be combined with
TMTV to improve early stratification in nodal PTCL.
MATERIALS AND METHODS
Patients
This retrospective analysis included 140 consecutive patients from
7 European centers (France, Belgium, Switzerland, and Denmark)
who, between April 2006 and May 2014, received a histologic diagnosis
of PTCL (PTCL-NOS, AITL, or ALCL). Six centers were members
of the Lymphoma Study Association. To be eligible, a patient had to
undergo baseline 18F-FDG PET/CT and a first-line anthracycline-based
chemotherapy. We evaluated all scans performed at initial diagnosis,
during treatment after 2 cycles of chemotherapy (iPET2), and during
treatment after 3 or 4 cycles of chemotherapy (iPET3/4), as well as
eotPET. In no case was therapy changed on the basis of the iPET
response, except for 3 patients in whom clinical progression was clearly
observed at iPET4, leading to second-line therapy. Clinical prognostic
indices, such as Ann Arbor stage, International Prognostic Index (IPI)
factors and score, bone marrow involvement on biopsy, and Prognostic
Index for Peripheral T-Cell Lymphoma (PIT) score (16), were evalu-
ated. Of the 140 patients, 108 were part of a previously published study
on the prognostic value of TMTV (5). In addition, 14 Danish patients
were part of another previously published study (14); in the current
study, the follow-up period of that previous study was extended from
29 to 47 mo. The current study was conducted in accordance with the
Helsinki declaration and was approved by the Ethical Committee with a
waiver of informed consent because of its retrospective, observational
nature. All the data were anonymized.
18F-FDG PET/CT
All the centers followed the recommended rules for performing
oncologic 18F-FDG PET/CT (17), using a Biograph Sensation 16
Hi-Rez (Siemens Medical Solutions), Gemini GXL or Gemini TOF
(Philips), or Discovery (GE Healthcare) scanner (18). Five centers were
accredited by EANM Research Ltd., one was accredited through a
French network for multicenter-trial quality control as previously re-
ported (5), and one followed the manufacturers’ guidelines. In every
center, the same scanner was used for both baseline and posttreatment
18F-FDG PET/CT. iPET was performed as recommended (19,20), as
close as possible to the successive cycles, and eotPET was performed
at least 3 wk after the last exposure of the patient to anticancer drugs.
Baseline TMTV, summing the metabolic volumes of all nodal and
extranodal lesions, was computed using the 41% SUVmax threshold
method (21) with semiautomatic software packages (Planet Onco, ver-
sion 2.0 [DOSIsoft], and the Beth Israel plug-in for FIJI [Fiji Is Just
ImageJ]) (22)). Bone marrow involvement was included in the volume
measurement only if there was focal uptake. The spleen was considered
involved if there was focal or diffuse uptake higher than 150% of the
liver background. Response on iPET and eotPETwas assessed using the
Deauville 5-point scale, with a score of 4–5 for positivity (18F-FDG
uptake higher than in the liver) (20). PET scans were independently
analyzed by 2 experienced nuclear medicine physicians. The percentage
decrease in SUVmax between PET0 and PET2 and between PET0 and
PET4 was calculated, with iPET2 being considered negative when the
former was greater than 66% (23) and iPET3/4 being considered neg-
ative when the latter was greater than 73% (24).
Statistical Analysis
PFS and OS were calculated according to the revised National
Cancer Institute criteria (19). Survival functions were estimated using
the Kaplan–Meier method and compared using the log-rank test. The
TMTV optimal cutoff for survival prediction was determined by
receiver-operating-characteristic analysis and X-tile software analysis.
Data obtained at iPET3/4 were grouped, and data obtained at iPET2 and
eotPETwere separately analyzed. Multivariate analyses were performed
using a Cox proportional-hazards model, testing each step of PET re-
sponse against IPI, PIT, or TMTV. Differences between the results of
comparative tests were considered significant if the 2-sided P value was
less than 0.05. Clinical and baseline PET data were combined with iPET
data whenever statistically relevant for PFS and OS prediction. Statis-
tical analysis was conducted using MedCalc software.
RESULTS
Baseline Patient Characteristics and Baseline
Prognostic Factors
The characteristics of the 140 patients enrolled in the study are
summarized in Table 1. Most patients were treated with CHOP or
a CHOP-like regimen, and the others received ACVBP (cyclo-
phosphamide, doxorubicin, vindesine, and bleomycin); one patient
received a regimen consisting of ifosfamide, cyclophosphamide,
and etoposide. Consolidation therapy with stem cell transplanta-
tion, either autologous (n 5 26) or allogeneic (n 5 6), was per-
formed on 32 patients under 60 y old.
With a median follow-up of 43 mo, the 2-y PFS and OS of the
whole population were 51% and 67%, respectively. The respective
2-y PFS and OS were 42% and 46% for PTCL-NOS, 43% and
67% for AITL, and 50% and 60% for ALK-negative ALCL. ALK-
positive ALCL patients had a much better outcome, with the median
PFS and OS not being reached (only 2 PFS and 1 OS events).
On univariate analysis (Table 2), an IPI greater than 2 and a
PIT greater than 1 were significantly associated with an inferior
TABLE 1
Baseline Patient Characteristics (n 5 140)
Characteristic Data
Median age (y) 59 (range, 17–85)
Age . 60 y 64 (46%)




ALK-negative ALCL 29 (21%)
ALK-positive ALCL 22 (16%)
Ann Arbor stage III–IV 121 (86%)
ECOG 2–3 42 (30%)
IPI . 2 68 (49%)
PIT . 1* 65 (46%)
Bone marrow biopsy involved* 33 (24%)
Increased serum LDH 74 (52%)
Consolidative transplantation 32 (23%)
TMTV . 230 cm3 65 (46%)
*136 patients with bone marrow biopsy data available.
LDH 5 lactate dehydrogenase.
Data are number followed by percentage in parentheses, except
for median age.
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prognosis for both PFS and OS, and positivity on BM biopsy was
significantly prognostic of PFS. Both receiver-operating-characteristic
analysis and X-tile analysis determined that the best TMTV cutoff for
predicting PFS (Miller–Seigmund P, 0.0001) and OS (P5 0.0047)
in this population was 230 cm3, as already published (5). TMTV was
highly predictive of outcome (P , 0.0001 for PFS and P 5 0.0002
for OS). In a multivariate analysis testing in 2 separate models,
baseline TMTV with IPI or PIT, only TMTV remained significant
for PFS (P 5 0.0004, hazard ratio [HR] 5 2.6, and P 5 0.0008,
HR5 2.5, respectively). For OS, TMTVand IPI or PITwere indepen-
dently prognostic (P 5 0.016, HR 5 2.1, and P 5 0.024, HR 5 2.0,
respectively, for IPI; P5 0.019, HR5 2.1, and P5 0.017, HR5 2.1,
respectively, for PIT).
We observed no significant impact of PFS or OS prognosis
on the chemotherapy regimen (CHOP vs. other regimens) or the
postinduction treatment (autologous stem cell transplantation vs.
standard consolidation).
Predictive Value of PET Response Assessment
Forty-three patients underwent iPET2, 95 underwent iPET3/4,
and 96 underwent eotPET. The positivity rates were 37% for
iPET2, 29% for iPET3/4, and 26% for eotPET (Fig. 1).
iPET2. On iPET2 (Figs. 2A and 2B), nearly all patients showing
positive results relapsed within 2 y: their 2-y PFS was 6%, com-
pared with 73% in the 63% of patients who achieved an early
complete metabolic response (P , 0.0001, HR 5 6.8). iPET2-
positive patients also had a much lower OS than iPET2-negative
patients, with a 2-y OS of 22%, compared with 84% (P , 0.0001,
HR 5 6.6). Patients with an SUVmax reduction of more than 66%
(n 5 33) also had a significantly better PFS (P 5 0.0003, HR 5
4.1) and OS (P 5 0.0001, HR 5 5.0), but an SUVmax reduction
was not more prognostic than a Deauville-scale cutoff of 4.
iPET3/4. iPET3/4 (Figs. 2C and 2D) showed similar differ-
ences: patients achieving negative iPET3/4 status had a much
TABLE 2
PET and Clinical Parameters Associated with PFS and OS on Univariate Analysis
2-y PFS 2-y OS
Parameter % 95% CI P HR % 95% CI P HR
TMTV
Low 68 58–73 ,0.0001 3.16 78 73–83 0.0004 2.79
High 31 26–36 52 46–58
iPET2
5-PS , 4 73 65–81 ,0.0001 8.07 84 77–91 0.0002 7.48
5-PS $ 4 6 0–12 22 11–33
iPET3/4
5-PS , 4 72 67–77 ,0.0001 6.11 85 80–90 ,0.0001 6.41
5-PS $ 4 10 4–16 32 23–41
eotPET
5-PS , 4 83 79–87 ,0.0001 15.11 94 91–97 ,0.0001 25.23
5-PS $ 4 6 1–11 27 18–36
IPI
#2 66 60–74 0.0005 2.33 79 76–84 0.0006 2.73
2 37 31–43 57 51–63
PIT
#1 65 60–70 0.0003 2.50 80 75–85 0.0004 2.85
1 38 32–43 55 49–61
BMB
Negative 59 54–63 0.0094 1.94 70% 65–75 0.2 1.5
Positive 30 22–38 61% 52–70
CI 5 confidence interval; 5-PS 5 score on Deauville 5-point scale; BMB 5 bone marrow biopsy.
FIGURE 1. Time frame distribution of PET studies. 1ve 5 PET-
positive.
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better prognosis, both for PFS and for OS (P , 0.0001 for both),
with 2-y estimates of 72% and 85%, respectively, compared with
16% and 32% in the iPET3/4-positive group. Among the 28
iPET3/4-positive patients, 25 progressed or relapsed and 19 died.
The positive predictive values of iPET3/4 for PFS and OS were 89%
and 68%, respectively, and the respective negative predictive values
were 69% and 81%. No significant difference in frequency of high
TMTV, high IPI, or age above 60 y was observed between
iPET3/4-positive and -negative patients. iPET3/4 remained a
strong prognosticator for AITL, PTCL-NOS, and ALK-negative
ALCL patients, for both PFS (P 5 0.0001, HR 5 4.8; P 5
0.0012, HR 5 4.8; and P 5 0.0002, HR 5 6.8, respectively)
and OS (P 5 0.0002, HR5 5.9; P 5 0.0163, HR 5 4.5; and P 5
0.0036, HR 5 5.4, respectively). iPET3/4 was not prognostic for
ALK-positive ALCL patients (for whom there was only one PFS
event). Patients with an SUVmax reduction of more than 73% (n 5
68) also had a significantly better PFS (P , 0.0001, HR 5 3.3) and
OS (P , 0.0001, HR 5 3.9).
eotPET. eotPET (Figs. 2E and 2F) was predictive of PFS and
OS (P , 0.0001): the respective 2-y PFS and OS were 85% and
96% for eotPET-negative patients versus 6% and 27% for eotPET-
positive patients. The positive predictive values were 96% and
84% and the negative predictive values were 80% and 91% for
PFS and OS, respectively. In a subanalysis,
eotPET maintained its predictive value for
both PFS and OS for the 2 largest groups:
AITL (P , 0.0001, HR 5 9.8, and P 5
0.0002, HR 5 7.7, respectively) and
PTCL-NOS (P 5 0.0001, HR 5 5.5, and
P , 0.0001, HR 5 12.3, respectively).
Evolution of PET Response During Treat-
ment. Twenty-three patients had both iPET2
and iPET3/4 evaluations (Fig. 1). Of the 6 of
23 iPET2-positive patients, 5 remained posi-
tive at iPET3/4 and 1 became negative. Two
iPET2-negative patients became positive at
iPET3/4.
Twenty-seven patients had both iPET2
and eotPET. Seven were iPET2-positive,
and of these, 4 (57%) remained positive at
eotPET. Interestingly, all 7 iPET2-positive
patients had PFS events during follow-up,
including the 4 who became negative at
eotPET.
In total, 67 patients had both iPET3/4
and eotPET: 16 were iPET3/4-positive, and
among these, 10 (63%) remained positive
at eotPET. Of the 6 patients who turned
negative between iPET3/4 and eotPET,
only 2 did not have PFS or OS events.
Twenty-eight patients did not undergo eotPET;
12 were iPET3/4-positive, and of these, 8
died during first-line therapy.
iPET Combined with
Baseline Parameters
When TMTV, the only statistically sig-
nificant baseline parameter on multivariate
analysis, was tested in a bivariate analysis
against iPET2 or iPET3/4, both factors
were independent predictors for PFS (0.0002 and 0.0078; P 5
0.0001 and P , 0.0001, respectively). For OS, both factors
were borderline-significant at iPET2 (P 5 0.054 for TMTV
and P 5 0.057 for iPET2), but at iPET3/4, PET response remained
significant (P , 0.0001) whereas TMTV had only borderline sig-
nificance (P 5 0.07). Therefore, we constructed a prognostic
model combining TMTV with early PET response. With iPET3/
4, TMTV stratified the population into 4 groups categorized by risk
(P , 0.0001, HR5 14.3; Fig. 3). Group 1, with a 2-y PFS of 79%,
included patients who had a TMTV of 230 cm3 or less and were
iPET3/4-negative (43/95, 45%). Group 2, with a 2-y PFS of 59%,
included patients who had a TMTVof more than 230 cm3 and were
iPET3/4-negative (24/95, 25%). Group 3, with a 2-y PFS of 42%,
included patients who had a TMTV of at least 230 cm3 and were
iPET3/4-positive (12/95, 13%). Group 4, with a 2-y PFS of 0%,
included patients who had a TMTV of more than 230 cm3 and
were iPET3/4-positive (16/95, 17%). The worst prognostic
group comprised 17% of the population but 35% of total events.
Among iPET3/4-negative patients (n 5 67), there was a trend
for a lower PFS in those with a high tumor burden than in those
with a low tumor burden (P 5 0.06). The OS of the whole pop-
ulation was also significantly stratified (P , 0.0001) according to
TMTV and iPET, with a 2-y OS of only 18% for the worst group
(Fig. 3).
FIGURE 2. Kaplan–Meier estimates of PFS and OS according to iPET2 (A and B), iPET3/4
(C and D), and eotPET (E and F). 1ve 5PET-positive; -ve 5 PET-negative.
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Similar results were found when iPET2 was combined with
TMTV (P , 0.0001 for PFS and P 5 0.0001 for OS; Fig. 3).
Patients with a high TMTV and a poor response included 30% of
the population but 59% of the total events. In a subanalysis of the
iPET2-negative group (n 5 27), the 7 patients with a high TMTV
had a lower PFS than the 20 with a low TMTV (P 5 0.0001, HR 5
11.8). Most patients in the iPET2-positive group had a baseline high
TMTV (13/16).
Clinical indices (IPI and PIT) and iPET2 or iPET3/4 were
independent predictive factors for PFS and OS on multivariate
analysis (Table 3, Supplemental Table 1; supplemental materials
are available at http://jnm.snmjournals.org). IPI or PIT (Supple-
mental Fig. 1) combined with iPET response significantly strat-
ified the population into 4 different risk groups for both PFS
and OS.
DISCUSSION
In this series of 140 PTCL patients
representing the major histologic entities
found in Europe, we observed that imaging
performed as early as iPET2 was able to
identify a subset of high-risk patients with a
poor outcome. This observation was further
confirmed at iPET3/4. The predictive value
of iPET is independent of baseline clinical
indices (IPI or PIT scores). This early
response could be combined with base-
line TMTV for better risk stratification.
Our results also emphasize the strong
prognostic value of eotPET for remission
assessment.
Early identification of high-risk patients
with PTCL is an important step toward
enabling testing of alternative therapeutic
approaches. More than 12 clinical indices
have been proposed to improve risk strat-
ification (16), but with unsatisfactory re-
sults. PET restaging has been evaluated
for this purpose in several studies (9–13,
15,25). However, these studies included
small numbers of patients, often fewer than
50, or comprised an admixture of primary-
nodal and extranodal PTCL subtypes, in-
cluding natural killer T-cell lymphoma,
which may account for half the population in a series (11,15).
Unlike nodal PTCL, which is a disseminated disease, extranodal
natural killer T-cell lymphoma presents more often at stage I or
II with small tumor burden. Some of the small, early studies did
not find any significant predictive value for iPET, possibly be-
cause of differences in the criteria used for PET reporting (12),
but patient selection was also a confounding factor (14). The
initial study from El-Galaly et al. (14) included patients with a
better prognosis, lower-risk IPI/PIT, less advanced stage (71%,
vs. 86% in the present study), and shorter follow-up. Our results,
although retrospective, rely on the largest multicenter series
assessing the predictive value of PET performed at different time
points during first-line therapy in the 4 main nodal PTCL enti-
ties, using the Deauville criteria for PET reporting. The positiv-
ity rate observed for early PET is within the range reported by
FIGURE 3. Kaplan–Meier estimates of PFS and OS according to iPET2 combined with
baseline TMTV (A and B) and iPET3/4 combined with TMTV (C and D). 1ve 5 PET-positive; -ve 5
PET-negative.
TABLE 3
Multivariate Analysis Testing IPI vs. iPET2, iPET3/4, or eotPET as Cofactor for Prediction of PFS and OS
PFS OS
Parameter HR 95% CI P HR 95% CI P
iPET2-positive 6.9 2.57–18.33 0.0001 5.7 1.86–17.22 0.0024
IPI . 2 3.9 1.51–10.04 0.0051 3.4 1.19–10.0 0.0231
iPET3/4-positive 7.0 3.79–12.87 ,0.0001 8.7 4.03–18.87 ,0.0001
IPI . 2 2.8 1.51–5.08 0.0011 4.2 1.97–9.12 0.0002
eotPET-positive 14.6 6.80–31.35 ,0.0001 23.9 8.74–65.16 ,0.0001
IPI . 2 1.5 0.74–2.90 NS 1.3 0.56–2.85 NS
CI 5 confidence interval; NS 5 not significant; corresponds to variable with P . 0.1.
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the other studies that have included a majority of nodal PTCL
(23%–31%). The data presented herein demonstrate that iPET
positivity can identify high-risk patients with a very high positive
predictive value. The 89% positive predictive value observed for
iPET3/4 positivity is much higher than the values reported for
other aggressive lymphomas, reflecting the number of high-risk
patients (33%) included in our population. Conversely, patients
who show a good response and iPET negativity have a favorable
outcome, superior to the expected outcome observed in the
PTCL population (4). eotPET confirmed but did not add much
prognostic value to iPET evaluation, with a slight increase in
positive predictive value from 89% to 96%. Indeed, although
37% of iPET3/4-positive patients achieved a complete meta-
bolic response at eotPET, 75% of these patients experienced
progression or died. The predictive value identified for iPET2
in this study agrees with the data recently reported from the
PETAL prospective multicenter trial (NCT00554164) (26). In
76 PTCL patients, iPET2 positivity (25% of the patients), de-
fined by an SUVmax decrease of 66% or less, was significantly
predictive of outcome, with a 2-y OS of 25%, versus 79% for
iPET2-negative patients (26). In the current study, the compar-
ison with Deauville scoring clearly shows that the approach
based on a percentage decrease in SUVmax has no advantage
in PTCL, probably because of the very bad prognosis for this
group of diseases. All these results confirm that iPET2, as a
marker a chemosensitivity, is a tool for early prediction of out-
come and can be used early on to determine whether a change
in therapy for PTCL is needed.
The second important finding of our study is that accounting
for baseline TMTV increased the predictive power of iPET.
By combining iPET with baseline TMTV, we improved risk
stratification for both iPET-positive and iPET-negative patients.
For instance, within the PET-negative group, baseline TMTV
defined a population with an excellent outcome, those with
a small metabolic volume, and a population with a more
moderate prognosis, those with a large metabolic volume.
One advantage of the relative method of volume measurement
used in this study is that, in principle, it is moderately affected
by differences in instrumentation, provided all the quality
controls are regularly performed and published guidelines are
followed (18). However, in future prospective trials, the use of a
filtered PET dataset for harmonized quantification should im-
prove the results obtained with the new devices (27). Similar
approaches combining baseline TMTVand early response have been
proposed for diffuse large B-cell lymphoma (28) and Hodgkin
lymphoma (29).
Finally, our findings suggest that it should also be possible to
stratify the risk of progression by combining early PET with cur-
rent prognostic indices, though such an approach would be less
predictive.
CONCLUSION
This large body of data in a rare and heterogeneous disease
provides the rationale to investigate alternative therapeutic strategies
for iPET-positive patients, who are, in the main, chemoresistant
to current first-line treatments. New drugs have been proposed
for patients with refractory PTCL, such as the histone deacetylase
inhibitor romidepsin or the anti-CD30 brentuximab in phase II
trials. Early guided therapy based on iPET2 response is important to
avoid undue treatment toxicity and improve the results of second-
line intensified treatment. In addition, the combination of iPET
data with baseline PET data identifies these poor-prognosis
patients earlier and could be a useful tool for PET-adapted therapy
in future trials.
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